JAC Advance Access originally published online on October 29, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 52, 987-992
© 2003 The British Society for Antimicrobial Chemotherapy
Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis
1 Centre for Pharmaceutical Research, School of Pharmaceutical, Molecular and Biomedical Sciences, University of South Australia, Adelaide; Departments of 2 Pharmacy, and 4 Microbiology and Infectious Diseases, Women’s and Children’s Hospital, North Adelaide, SA 5006, Australia; 3 Regional Adult Cystic Fibrosis Unit, Seacroft Hospital, Leeds, UK
Received 27 March 2003; returned 30 June 2003; revised 5 August 2003; accepted 9 September 2003
Objectives: To define the steady-state pharmacokinetics of colistin methanesulphonate and colistin in patients with cystic fibrosis (CF) following intravenous administration of the former.
Materials and methods: The study was conducted in 12 patients with CF following intravenous administration of colistin methanesulphonate (1.63–3.11 mg/kg) every 8 h for at least 2 days. On the day of study, four blood samples were collected from each patient at 60, 120, 240 and 360 min after the end of the infusion. Concentrations of colistin methanesulphonate and colistin in plasma were measured separately by HPLC.
Results: At steady-state, colistin methanesulphonate had a mean (± S.D.) total body clearance, volume of distribution and half-life of 2.01 ± 0.46 mL/min per kg, 340 ± 95 mL/kg and 124 ± 52 min, respectively. Colistin had a significantly longer mean half-life of 251 ± 79 min (P < 0.001). With the regimen used, colistin methanesulphonate was well tolerated. This is the first report on the pharmacokinetics of colistin methanesulphonate in CF patients determined using concentrations of colistin methanesulphonate and colistin in plasma.
Conclusions: Based on the in vitro pharmacodynamics against Pseudomonas aeruginosa previously published by our group and these pharmacokinetic findings, dose escalating trials may be warranted to maximize efficacy.
Keywords: colistin, HPLC, pharmacodynamics, Pseudomonas
* Present address. Victorian College of Pharmacy, Monash University, Parkville, Victoria 3052, Australia.
Corresponding author. Tel: +61-8-8161-7350; Fax: +61-8-8161-6049; E-mail: coulthardk{at}wch.sa.gov.au
¶ Present address. Victorian College of Pharmacy, Monash University, Parkville, Victoria 3052, Australia.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Souli, P. D. Rekatsina, Z. Chryssouli, I. Galani, H. Giamarellou, and K. Kanellakopoulou Does the Activity of the Combination of Imipenem and Colistin In Vitro Exceed the Problem of Resistance in Metallo-{beta}-Lactamase-Producing Klebsiella pneumoniae Isolates? Antimicrob. Agents Chemother., May 1, 2009; 53(5): 2133 - 2135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Poudyal, B. P. Howden, J. M. Bell, W. Gao, R. J. Owen, J. D. Turnidge, R. L. Nation, and J. Li In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae J. Antimicrob. Chemother., December 1, 2008; 62(6): 1311 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Wallace, J. Li, Craig. R. Rayner, K. Coulthard, and R. L. Nation Stability of Colistin Methanesulfonate in Pharmaceutical Products and Solutions for Administration to Patients Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3047 - 3051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Landman, C. Georgescu, D. A. Martin, and J. Quale Polymyxins Revisited Clin. Microbiol. Rev., July 1, 2008; 21(3): 449 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Bergen, J. Li, R. L. Nation, J. D. Turnidge, K. Coulthard, and R. W. Milne Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model J. Antimicrob. Chemother., March 1, 2008; 61(3): 636 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Wallace, J. Li, R. L. Nation, C. R. Rayner, D. Taylor, D. Middleton, R. W. Milne, K. Coulthard, and J. D. Turnidge Subacute Toxicity of Colistin Methanesulfonate in Rats: Comparison of Various Intravenous Dosage Regimens Antimicrob. Agents Chemother., March 1, 2008; 52(3): 1159 - 1161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Hawley, C. K. Murray, and J. H. Jorgensen Colistin Heteroresistance in Acinetobacter and Its Association with Previous Colistin Therapy Antimicrob. Agents Chemother., January 1, 2008; 52(1): 351 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Tan, J. Li, and R. L. Nation Activity of Colistin against Heteroresistant Acinetobacter baumannii and Emergence of Resistance in an In Vitro Pharmacokinetic/Pharmacodynamic Model Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3413 - 3415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Owen, J. Li, R. L. Nation, and D. Spelman In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates J. Antimicrob. Chemother., March 1, 2007; 59(3): 473 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Li, C. R. Rayner, R. L. Nation, R. J. Owen, D. Spelman, K. E. Tan, and L. Liolios Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 2946 - 2950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Li and R. L. Nation Comment on: Pharmacokinetics of inhaled colistin in patients with cystic fibrosis J. Antimicrob. Chemother., July 1, 2006; 58(1): 222 - 223. [Full Text] [PDF]
|
|
|
|
|
|
P. J. Bergen, J. Li, C. R. Rayner, and R. L. Nation Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 1953 - 1958. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ratjen, E. Rietschel, D. Kasel, R. Schwiertz, K. Starke, H. Beier, S. van Koningsbruggen, and H. Grasemann Pharmacokinetics of inhaled colistin in patients with cystic fibrosis J. Antimicrob. Chemother., February 1, 2006; 57(2): 306 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Jones, T. R. Anderegg, J. M. Swenson, and The Quality Control Working Group Quality Control Guidelines for Testing Gram-Negative Control Strains with Polymyxin B and Colistin (Polymyxin E) by Standardized Methods J. Clin. Microbiol., February 1, 2005; 43(2): 925 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hogardt, S. Schmoldt, M. Gotzfried, K. Adler, and J. Heesemann Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients J. Antimicrob. Chemother., December 1, 2004; 54(6): 1057 - 1061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Li, R. W. Milne, R. L. Nation, J. D. Turnidge, T. C. Smeaton, and K. Coulthard Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate J. Antimicrob. Chemother., May 1, 2004; 53(5): 837 - 840. [Abstract] [Full Text] [PDF]
|
|